Combines Achilles' best-in-class AI-driven, tumor-targeting technology with Arcturus' world-leading self- amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND- enabling studies LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical- stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with Arcturus T ...